Xilio Therapeutics Q3 EPS $(0.61) Beats $(0.81) Estimate
Portfolio Pulse from Benzinga Newsdesk
Xilio Therapeutics reported Q3 losses of $(0.61) per share, beating the analyst consensus estimate of $(0.81) by 24.69 percent. This represents a 15.28 percent increase over losses from the same period last year.
November 09, 2023 | 9:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xilio Therapeutics' Q3 losses were less than expected, indicating a potential improvement in the company's financial performance.
Xilio Therapeutics reported lower than expected losses for Q3, which is a positive sign for the company's financial health. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100